Thermo Fisher Scientific Expands Millersburg, Pa. Bioprocessing Manufacturing Site
$40 million expansion will support increased production of single-use technology for critical vaccines and biologics
Thermo Fisher Scientific is investing $40 million to expand its single-use technology (SUT) manufacturing facility in Millersburg, Pa. The expansion is part of the company’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19.
Single-use technologies enable development of a growing number of biological drugs and vaccines, creating unprecedented demand for these products. The Millersburg site expansion will add significant capacity to continue providing the biopharma industry with the technology and materials needed to assist in developing new vaccines, cancer treatments and breakthrough therapies for other conditions.
“Since the start of the pandemic, the Millersburg site has been instrumental in supporting more than 20 pharmaceutical partners developing lifesaving therapies and vaccines,” said Mitch Kennedy, president, single use technologies, Thermo Fisher Scientific. “During the pandemic, our colleagues in Millersburg and around the world answered the call for increased production. Our expanded bioprocessing capabilities will ensure that we can continue to deliver essential supplies to our customers as demand surges.”
Thermo Fisher acquired the Millersburg facility in 2015, and over the last two years has expanded and modernised the warehouse and clean rooms. The second phase of the site expansion includes a new, 47,000-square-foot warehouse and creation of 100 new jobs at various levels. Once fully renovated by mid 2023, Thermo Fisher anticipates that the site will employ more than 1,000 people.
“Pennsylvania is proud that Thermo Fisher Scientific is expanding in Dauphin County and is creating 100 new jobs in the region,” said Governor Tom Wolf. “Pennsylvania is a key destination for groundbreaking businesses with our highly educated, skilled, and talented workforce, leading universities, and location near other major cities. The bioprocessing solutions that Thermo Fisher Scientific will produce in Millersburg will help to power the local economy and strengthen our position in the science and technology sectors.”
“We are tremendously grateful for the vision, investment and job creation Thermo Fisher Scientific is bringing to Millersburg and our hardworking local families,” said U.S. Representative, Scott Perry. “We know our folks will continue to make this world-class company and our community proud.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...